TheraVaxB (Therapeutic HBV Vaccine)

There are 300 million people in the world infected by HB virus. Among them, 100 million are in China. About 20-30 millions of patients will develop chronic hepatitis every year. Chronic hepatitis is a major cause of hepatocellular carcinoma (e.g. the liver cancer). About 300,000 people will die every year from liver cancer caused by chronic HBV infection. For that reason, the prevention and treatment of hepatitis caused by HBV have been listed as one of the sixteen major tasks that China has called a nationwide fight.

In 2009, during the 14th annual conference of “Treatment of Viral Infection Caused Liver Disease” organized by the China Medical Society, experts agreed that a regiment that combines anti-viral drugs and immune therapy must be applied in order to cure the disease. Also, only when anti-viral drug and immune therapy being incorporated in a proper order,  better control of viral replication and eventually eliminate the virus from body can be achieved. Therefore, it is critical for clinical physicians to pay more attention to apply immune therapy into treatment of chronic patients.

ImmuOn Therapeutics is formed by a team of veteran scientists. Some of them once worked with Chiron, the company that developed world’s first prophylactic HBV vaccine and entered into clinical trial for therapeutic vaccines. Not only we have rich experience on designing and developing the vaccine, but also have firsthand experience in designing and conducting clinical trials for therapeutic HBV vaccine.

Our TheraVaxB™ has a unique combination of multi-antigens and powerful adjuvants that would raise both B cell and T cell responses. A full scale of immune response is the fundamental mechanism to break immune tolerance and eventually cure the patients.